BTKi Plus BCL-2i Combination Therapy in CLL: Safety, Lead-In Strategies, and Patient Counseling

Experts have outlined key considerations for counseling patients with chronic lymphocytic leukemia (CLL) who are receiving combination therapy with a BTK inhibitor and venetoclax, emphasizing the need to balance efficacy with safety when presenting treatment options.

Patients receiving venetoclax may experience neutropenia and an increased risk of infections, but the advantage of a fixed-duration regimen is that adverse events typically resolve once therapy is completed. BTK inhibitors, if used in fixed duration, limit cumulative exposure and reduce the likelihood of long-term side effects such as atrial fibrillation and hypertension. Zanubrutinib appears to have a favorable safety profile, making it a suitable partner for venetoclax in combination therapy.

Individual disease characteristics should guide therapy selection. Patients with bulky lymphadenopathy or symptomatic disease may benefit from a BTK inhibitor lead-in, which helps reduce tumor burden before adding venetoclax and mitigates the risk of tumor lysis syndrome. This approach also allows for a deeper response in both blood and nodal compartments, which might not be achieved with venetoclax alone in certain patients.

The importance of all-oral regimens for patient convenience was noted, avoiding infusion-related complications associated with therapies like obinutuzumab. The BTK lead-in not only facilitates safer venetoclax administration but also improves tolerability for patients with extensive disease.

Therapy selection involves a nuanced assessment of disease burden, risk profile, and patient preference, in addition to the expected safety profile. Combining BTK inhibitors with BCL-2-targeted therapy can be particularly beneficial for patients with high disease burden, symptomatic lymphadenopathy, or a need for a rapid and deep response, highlighting the importance of individualized treatment planning in CLL.